北京时间5月15日收盘,PASG市盈率为-17.41,PASG市值为8亿美元

PASG简介

PassageBIO,Inc.isageneticmedicinescompanyfocusedondevelopingtransformativetherapiesforrare,monogenicCNSdisorderswithlimitedornoapprovedtreatmentoptions.Itsvisionistobecomethepremiergeneticmedicinescompanybydevelopingandultimatelycommercializingtherapiesthatdramaticallyandpositivelytransformthelivesofpatientssufferingfromtheselife-threateningdisorders.Toachieveitsvision,ithasassembledaworld-classteamwhosemembershavedecadesofcollectiveexperienceingeneticmedicinesandrarediseasedrugdevelopmentandcommercialization.Thefieldofgeneticmedicineisrapidlyexpandinganditbelieveithasadifferentiatedapproachtodevelopingtreatmentsforrare,monogenicCNSdisordersthatenablesittoselectandadvanceproductcandidateswithahigherprobabilityoftechnicalandregulatorysuccess.IthasenteredintoastrategicresearchcollaborationwithPennu0027sGTP,headedbyDr.JamesWilson,aleaderinthegeneticmedicinesfield.Throughthiscollaborationithasassembledadeepportfolioofgeneticmedicineproductcandidates,includingitsthreeleadproductcandidates:PBGM01forthetreatmentofGM1,PBFT02forthetreatmentofFTDandPBKR03forthetreatmentofKrabbedisease.